Delivery Order SPE2DB25D3202-SPE2DB25FTAVB
- Not listed
- The Defense Logistics Agency awarded a $34,576.32 firm fixed price delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Xolair 150 mg/ml syringes. This non-set-aside competitive award is scheduled for completion by June 24, 2025, and represents a child delivery order under AmerisourceBergen's larger contract vehicle with DLA. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for...
- The Defense Logistics Agency awarded a $72,034 delivery order to AmerisourceBergen Drug Corp on July 3, 2025, for the supply of Xolair 150 mg/mL syringes, with completion scheduled for July 25, 2025. This firm fixed-price, non-set-aside contract is being performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at...
- The Defense Logistics Agency awarded a $5,762.72 delivery order to AmerisourceBergen Drug Corp for the supply of Xolair 150 mg/ml syringes, with an ultimate completion date of August 28, 2025. This is a firm fixed price delivery order with no set-aside designation, executed as a competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly for military...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Xolair 150 mg/ml syringes, with a contract ceiling value of $5,402.58 and an ultimate completion date of August 19, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion pharmaceutical supply vehicle...
- The Defense Logistics Agency awarded a $10,393.14 firm fixed price delivery order to AmerisourceBergen Drug Corp for XOLAIR 300 mg/2 mL syringes on July 9, 2025, with completion targeted for July 30, 2025. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The pharmaceutical distributor, headquartered in Conshohocken,...
- The Defense Logistics Agency awarded a $3,601.70 delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for Xolair 150 mg/mL syringes, with an ultimate completion date of August 13, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is being performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- The Defense Logistics Agency awarded a $30,254.28 firm fixed price delivery order to AmerisourceBergen Drug Corp for Xolair 150 mg/ml syringes, with an ultimate completion date of July 10, 2025. This non-set-aside contract was competitively awarded on June 17, 2025, with performance to be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,644.08 to AmerisourceBergen Drug Corp for the supply of Xolair 150 mg/ml syringes. This competitively awarded, firm fixed-price contract was issued on April 24, 2025, with an ultimate completion date of May 15, 2025. The contract will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded a delivery order valued at $14,406.80 to AmerisourceBergen Drug Corp for the supply of XOLAIR 150 mg/ml syringes, with an ultimate completion date of August 1, 2025. This is a firm fixed price, competitively awarded delivery order with no set-aside designation. The award was issued on July 11, 2025, and the product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, the company's corporate headquarters and primary distribution...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Xolair 150 mg/mL syringes, valued at $10,805.10. This is a firm fixed-price delivery order with a completion date of August 20, 2025, and will be performed at the contractor's Conshohocken, Pennsylvania facility. The award was made through open competition with no set-aside designation, reflecting AmerisourceBergen's proven capability to meet federal pharmaceutical procurement...
- SPE2DB25D3202Indefinite Delivery Contract
- SPE2DB25D3202-SPE2DB25FTAVBDelivery Order
The Defense Logistics Agency awarded a $2,881.36 delivery order to AmerisourceBergen Drug Corp on June 27, 2025, for the supply of Xolair 150 mg/mL syringes, with completion targeted for July 21, 2025. This firm fixed-price delivery order, which carries no set-aside designation, represents a competitive award under the company's existing contract vehicle with DLA. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving the federal medical procurement market and holds a significant Indefinite Delivery Contract (IDC) valued at $999,999,999.00 with DLA Troop Support Medical through December 2026. The delivery order falls under AmerisourceBergen's comprehensive pharmaceutical supply agreement with DLA, which enables the company to distribute a broad range of medications, vaccines, medical devices, and specialized healthcare commodities to support military healthcare systems and other federal agencies. Xolair (omalizumab) is a biologic immunosuppressant used primarily in the treatment of moderate-to-severe allergic asthma and chronic urticaria, making this procurement consistent with the company's portfolio of specialty medications supporting Defense Health Agency and other military health requirements. The relatively modest order value reflects the typical transaction sizes under the DLA pharmaceutical distribution program, which encompasses numerous small-value delivery orders alongside larger medical supply shipments.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.9k | 6/27/25 |